# Medical Cannabis Research Act of 2022

Right now, researchers who want to study medical cannabis face a major roadblock: it's classified as a Schedule I drug under federal law, which means the government treats it the same way as heroin or LSD. This classification makes it extremely difficult for scientists to get permission to conduct research, even though many states have already legalized cannabis for medical use. The Medical Cannabis Research Act aims to fix this problem by making it easier for legitimate researchers to study how cannabis might help patients with various medical conditions.

The bill would remove some of the federal barriers that currently prevent medical cannabis research from happening. Specifically, it would allow researchers to access cannabis for studies without jumping through as many bureaucratic hoops, and it would make it simpler for the Drug Enforcement Administration (DEA) to approve research applications. This means scientists could more easily investigate whether cannabis is effective for treating conditions like chronic pain, epilepsy, PTSD, nausea from chemotherapy, and other health issues where patients and doctors believe it might help.

**Who this affects:** This bill primarily impacts medical researchers, universities, and pharmaceutical companies interested in studying cannabis. It could also indirectly benefit patients by potentially leading to better evidence about whether cannabis treatments actually work and which ones are safest. It doesn't legalize cannabis for personal use or change state laws—it simply removes federal obstacles to scientific research. The bill essentially acknowledges that the current restrictions on studying cannabis are preventing the kind of rigorous medical science that could help doctors make better decisions about whether to recommend it to patients.

Medical Cannabis Research Act of 2022

Gaetz, Matt

Medical Cannabis Research Act of 2022 This bill establishes a new, separate registration process for manufacturers of cannabis for research. As a part of this process, the Drug Enforcement Administration must annually assess whether there is an adequate and uninterrupted supply of research cannabis and register additional manufacturers. The bill also authorizes health care providers of the Department of Veterans Affairs to provide information to veterans regarding participation in federally approved cannabis clinical trials.